BMS-927711, also known as Rimegepant, is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist used as an active pharmaceutical ingredient (API) in medications for the acute treatment and preventive treatment of migraine in adults. It functions by blocking CGRP receptors, which are involved in migraine pathophysiology, thereby alleviating symptoms such as headache, nausea, photophobia, and phonophobia. As a high-purity chemical compound (typically ≥97.5%), it is suitable for pharmaceutical research, development, and manufacturing of oral formulations, including orally disintegrating tablets, providing a convenient option for patients seeking rapid relief without invasive methods or gastrointestinal side effects common in other treatments. Clinical studies demonstrate its efficacy in reducing migraine severity, decreasing the need for rescue medications, and enhancing quality of life for migraine sufferers.